Allianthera (suzhou) Biopharmaceuticals Co., Ltd.

This early-stage trial tested a new oral drug called YUQ-A1007 in 47 healthy adults aged 18 to 65. The drug is designed to activate a protein in the gut that may help treat inflammatory bowel disease (IBD). The main goal was to check the drug's safety, tolerability, and how the b…